Through a meta-analysis, we comprehensively evaluated the clinical efficacy and safety of Kangfuxin liquid (KFXL) in patients with recurrent aphthous stomatitis (RAS). Randomized controlled clinical trials (RCTs) involving RAS patients treated with KFXL were systematically retrieved from several online databases from inception to December 2021. All the study selection, data extraction, and quality assessments were performed by two independent investigators using the Cochrane systematic review method. The total effective rate, VAS pain score, recurrence rate, and ulcer healing time were analyzed using Rev Man 5.3 software and Stata 16.0. A total of 17 studies consisting of 1703 patients were included in our investigation. The pooled result indicated that when compared with watermelon frost spray (WFS), KFXL had a significantly superior clinical effectiveness rate (logRR = 0.19, 95% CI: 0.15 to 0.22, P < 0.00001). Moreover, the ulcer healing time (MD = –1.63, 95% CI = –2.32 to –0.93, P < 0.00001), VAS pain score (MD = –1.81, 95% CI: –2.65 to –0.97, P = 0.00), and recurrence rate (logRR = –0.65, 95% CI = –0.89 to 0.42, P < 0.00001) of patients with RAS were also significantly improved after receiving the KFXL therapy. Our study revealed that KFXL was a more effective treatment for RAS than WFS, and it could significantly decrease the VAS pain score, recurrence rate, and ulcer healing time in patients. However, our study was limited by the quality of available literature, and further robust trials are needed for a more accurate analysis.
>
>